GSAI Development Clinical candidates Pharma/Nutraceutical/formulated ink-related
GSAI is developing a pipeline of novel therapeutics (or) Nutraceuticals (or) formulated inks that have the potential to improve the lives of patients. Each program is based on a scientific rationale to identify and treat patients most likely to respond to GSAI’s targeted therapies. Click on a Project/Program below.
(1) GS-7000
(2) GS-5000
(3) GS-5023
(4) GS-9000
(5) GS-5002
GSAI also identifies a select subset of promising early stage compounds from its product portfolio and positions them for development in markets worldwide.GSAI seeks opportunities in therapeutic areas with significant market potential and unmet medical need, where the compound has a competitive advantage, strong patent position worldwide, and a clear clinical development path.